查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
三阴性乳癌市场:KOL的洞察
市场调查报告书
商品编码
1719510

三阴性乳癌市场:KOL的洞察

KOL Insight - Breast Cancer - Triple Negative
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

这份综合报告提供了来自美国和欧洲的12位 KOL（关键意见领袖）对三阴性乳癌 (TNBC) 治疗的现状和未来的宝贵见解。本报告研究了临床试验对 Keytruda 采用和意义的影响，评估了数据法的变革潜力，并考虑了 sacituzumab-tilmotecan 等新兴疗法的作用。本报告指出了三阴性乳癌治疗中尚未满足的重大需求，并预测了未来五年治疗演算法将如何变化。详细了解已上市和正在研发的疗法及其临床数据以及重塑治疗方法的潜力。

主要问题解答

  • 1.针对不同类别的 TNBC 患者和治疗线，可选择的治疗方法有哪些？
  • 2.标靶治疗在疗效、耐受性和易用性方面有何比较？
  • 3.哪些临床试验可能对未来的处方趋势产生最大影响？
  • 4.一种药物需要具备哪些特征才能成为同类药物中的首选治疗药物？
  • 5.目前正在开发和筹备中的产品将如何影响未来的治疗偏好和方法？
  • 6.新疗法必须达到哪些疗效和耐受性终点才能有效竞争？
  • 7.哪些正在研发的疗法最有前景？它们将如何影响市场上的现有企业？
  • 8.预期不同患者族群的治疗前景将如何改变？

领导品牌

  • Lynparza
  • Talzenna
  • Tecentriq
  • Keytruda
  • Trodelvy
  • Enhertu
  • Bavencio
  • Zejula
  • Datroway
  • veliparib
  • sacituzumab tirumotecan

部分与会专家名单

  • 杜克大学医学教授、放射肿瘤学系教授、北卡罗莱纳州达勒姆市杜克大学乳房临床研究中心共同主任。
  • 耶鲁大学医学院耶鲁癌症中心教授。
  • 匹兹堡大学医学院教授。
  • 维也纳医科大学（奥地利维也纳）医学副教授和肿瘤内科医师。
  • 义大利摩德纳大学医院肿瘤学和血液学系肿瘤学副教授；乳房肿瘤科专家。
  • 英国牛津癌症中 心肿瘤内科顾问医师与英国牛津大学资深临床研究员。

方法论：

《治疗趋势》报告是透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，了解主要疾病领域的当前和未来治疗前景而编写的。 KOL 是根据严格的筛选标准精心挑选出来的，包括全球声誉、临床专业知识和其在治疗领域的影响力。每次访谈都遵循精心设计的讨论指南。这些指南是与 KOL 合作开发的，并经过行业专家的同行评审，以确保问题全面且与当前市场动态相关。透过在每份报告发布后12个月的持续市场监测，我们及时提供来自 KOL 的重大新闻事件、市场变化和市场发展的更新。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供深入、可行的见解。我们深厚的行业知识使我们能够提供相关且有价值的见解，帮助我们的客户了解新兴趋势并有效地解决复杂的挑战。我们的报告以广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解为后盾，为您提供所需的准确性和可信度。独家采访和数据以及持续的市场监控使我们能够全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包含 KOL 洞察和定量医生调查的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策并在快速变化的行业中保持竞争力。

简介目录

This comprehensive report delves into the current and future landscape of triple-negative breast cancer (TNBC) treatments, offering valuable insights from 12 key opinion leaders (KOLs) across the US and Europe. It examines the influence of clinical trials on the adoption and significance of Keytruda, evaluates the transformative potential of Datroway, and considers the role of emerging therapies like sacituzumab tirumotecan. The report highlights significant unmet needs in TNBC treatment and anticipates shifts in treatment algorithms over the next five years. Gain a detailed understanding of both marketed and pipeline therapies, alongside their clinical data and potential to reshape therapeutic approaches.

Key Questions Answered:

  • 1. What is the treatment of choice for each TNBC patient segment and line of therapy?
  • 2. How do targeted therapies compare in terms of efficacy, tolerability, and ease of administration?
  • 3. Which clinical trials are most likely to impact future prescribing trends?
  • 4. What are the necessary attributes for a drug to become the preferred treatment in its category?
  • 5. How will current and pipeline products affect future treatment preferences and lines of therapy?
  • 6. What efficacy and tolerability endpoints must new therapies achieve to compete effectively?
  • 7. Which pipeline therapies hold the most promise and how will they influence existing market players?
  • 8. How is the treatment landscape expected to evolve across different patient segments?

Key Brands:

  • Lynparza
  • Talzenna
  • Tecentriq
  • Keytruda
  • Trodelvy
  • Enhertu
  • Bavencio
  • Zejula
  • Datroway
  • veliparib
  • sacituzumab tirumotecan

Partial List of Participating Experts:

  • Medical Professor of Radiation Oncology and Co-Director of the Breast Clinical Research Unit at Duke University, Durham, NC.
  • Professor of Medicine at Yale Cancer Center, Yale School of Medicine, New Haven, CT.
  • Professor of Medicine at the University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Associate Professor of Medicine, Consultant Medical Oncologist at the Medical University of Vienna, Vienna, Austria.
  • Associate Professor of Oncology, and Breast Oncology Specialist at the Department of Oncology and Haematology, University Hospital of Modena, Modena, Italy.
  • Consultant Medical Oncologist at the Oxford Cancer Centre and Senior Clinical Researcher at the University of Oxford, Oxford, UK.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.